Remedi Breaks Into 2,301 Medical Institutions in India…Expects Expanded Public Procurement in Southeast Asia
Predicted impact: Low
Entry into Indian hospitals; market expansion with no revenue size given.
Remedi레메디
387690 · KOSDAQ · ₩387690 · 레메디
₩13,290▲ ₩580 (4.56%)End-of-day · Oct 26, 2026 · End-of-day prices.
Price · 1Y −39.59%
- Market cap
- ₩101B
- Enterprise value
- ₩104B
- P/E
- —
- P/B
- 6.4×
- Dividend yield
- —
- ROE
- —
- Net margin
- —
Trailing 12 months from filed financial statements, as of H1 2026.
52-week range−61.6% from the high
₩6,980Today: ₩12,640 – ₩13,840₩34,650
Returns
- 1W−19.1%
- 1M−29.5%
- 3M+38.6%
- 6M—
- YTD−39.6%
- 1Y—
- Volume today
- 318,829
- 0.2× the 20-day average
- Traded today
- ₩4.2B
- Listed shares
- 7,625,791
- EPS (12 months)
- —
AI researchResearch not started yetResearch starts once this company's financial statements are available.IPOListed Jul 13, 2026 at ₩20,700IPO details →
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 31 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: Routine filing about a shareholders' meeting with no details on outcomes. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-22.2% over the last month; the price is below its 20-day average.
- News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Remedi stock overview
Remedi (레메디, KRX: 387690) is listed on KOSDAQ, in the Medical & precision devices sector. Its shares closed at ₩13,290 on Oct 26, 2026, up 4.56% on the day, giving it a market value of ₩101B.
Key facts
- Market cap
- ₩101B
- Sector
- Medical & precision devices
- Latest price change
- +4.56%
- As of
- Oct 26, 2026
Quick answers about Remedi
- What is the market cap of Remedi?
- The market capitalisation of Remedi was ₩101B at the close on Oct 26, 2026.
- Who are the largest shareholders of Remedi?
- According to the latest official filings, the largest reported holders are Lee Re-na (44.26%, as of Jul 20, 2026); Kim Hyun-seop (2.21%, as of Jul 14, 2026); Jo Bong-ho (0.34%, as of Jul 16, 2026).
- When is the next earnings report from Remedi?
- Korean companies rarely announce results dates in advance. Based on when Remedi filed the same report in past years, its next 2q results is expected around Aug 14, 2027.
Company profile
Loading data for this company — check back soon
- Korean name
- 레메디
- Themes
- Medical devices
- CEO
- 조봉호
- Founded
- Jul 2012
- Listed
- Jul 2026
- Listed shares
- 7,625,791
- Fiscal year ends
- Month 12
- Website
- www.remedihc.com
Similar companies
- TSE131290 · ₩2.7T₩241,000−6.23%
- Classys214150 · ₩1.8T₩27,200−1.98%
- Kctech281820 · ₩1.7T₩86,400−8.67%
- Park Systems140860 · ₩1.6T₩223,000−6.30%
- Seers458870 · ₩1.1T₩27,850+17.51%
- DI003160 · ₩1T₩36,100−3.35%
- Curiox Biosystems445680 · ₩1T₩58,700−2.17%
- LivsMed491000 · ₩923B₩36,550−3.82%
Recent news
Remedy Proves Profitable Technology in India, AI Diagnostics Become New Growth Driver
Predicted impact: Low· Actual: −10.8% vs sector, volume 0.4× normal (5 trading days)
Vague growth story on India and AI diagnostics; no size or figures given.
Recent filings
See all- Results of Extraordinary Shareholders' MeetingOct 27, 2026
- Notice of shareholders' meetingOct 12, 2026
- Shareholders' meeting calledSep 15, 2026
- Determination of Shareholder Register Closure Period or Record DateSep 15, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: Remedi / 레메디 / 387690 / KRX:387690
Source: KRX statistical information